Patent Number: 8,816,073

Title: Matrix metalloproteinase inhibitors

Abstract: The present invention relates to .beta.-hydroxy and amino-substituted carboxylic acids, which act as matrix metalloproteinase inhibitors, particularly diastereomerically pure .beta.-hydroxy carboxylic acids, corresponding processes for their synthesis, and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune, and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase.

Inventors: Sattigeri; Viswajanani J. (Gurgaon, IN), Palle; Venkata P. (Pune, IN), Khera; Manoj Kumar (Gurgaon, IN), Reddy; Ranadheer (Suryapet, IN), Tiwari; Manoj Kumar (Mumbai, IN), Soni; Ajay (New Delhi, IN), Rauf; Abdul Rehman Abdul (Buldane, IN), Joseph; Sony (Ernakulam, IN), Musib; Arpita (Bankura, IN), Dastidar; Sunanda G. (New Delhi, IN), Sricastava; Punit Kumar (Guraon, IN)

Assignee: Ranbaxy Laboratories Limited

International Classification: C07D 401/06 (20060101); C07D 401/14 (20060101); A61P 19/02 (20060101); A61K 31/53 (20060101)

Expiration Date: 8/26/12018